Chronic Hand Eczema and Other Regional Eczemas
The FDA’s approval of delgocitinib for chronic hand eczema is shining a light on this and other regional eczemas. Next Steps in Derm, in partnership with the ODAC Dermatology Conference, interviewed Peter A. Lio, MD, FAAD, clinical assistant professor of dermatology and pediatrics at the Northwestern University Feinberg School of Medicine. Watch as Dr. Lio shares the burden of chronic hand eczem …
The FDA’s approval of delgocitinib for chronic hand eczema is shining a light on this and other regional eczemas. Next Steps in Derm, in partnership with the ODAC Dermatology Conference, interviewed Peter A. Lio, MD, FAAD, clinical assistant professor of dermatology and pediatrics at the Northwestern University Feinberg School of Medicine. Watch as Dr. Lio shares the burden of chronic hand eczem … Continue reading "Chronic Hand Eczema and Other Regional Eczemas"
Delgocitinib is a topical pan-Janus kinase (JAK) inhibitor that represents a novel non-steroidal treatment mechanism for chronic hand dermatitis. As a pan-JAK inhibitor, delgocitinib blocks all four members of the JAK family (JAK1, JAK2, JAK3, and tyrosine kinase 2 (TYK2)), thus simultaneously modulating the many cytokine pathways that drive chronic inflammatory skin disorders. Delgocitinib was in … 
Scarring alopecias in skin of color are increasingly recognized and remain a major cause of irreversible hair loss. During the 2025 Skin of Color Update in New York City, Susan C. Taylor, MD, presented an updated clinical approach to identifying and managing lichen planopilaris (LPP), frontal fibrosing alopecia (FFA), and central centrifugal cicatricial alopecia (CCCA) with a focus on early detect …